<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PONE-RA-07717R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0004661</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Biophysics</subject><subject>Computational Biology</subject><subject>Biochemistry/Bioinformatics</subject></subj-group></article-categories><title-group><article-title>Predicting Novel Features of Toll-Like Receptor 3 Signaling in Macrophages</article-title><alt-title alt-title-type="running-head">Rewiring the TLR3 Signaling</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Helmy</surname><given-names>Mohamed</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gohda</surname><given-names>Jin</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Inoue</surname><given-names>Jun-ichiro</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tomita</surname><given-names>Masaru</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tsuchiya</surname><given-names>Masa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Selvarajoo</surname><given-names>Kumar</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Systems Biology Program, School of Media and Governance, Keio University, Fujisawa, Japan</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Division of Cellular and Molecular Biology, Institute of Medical Science, University of Tokyo, Tokyo, Japan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Unutmaz</surname><given-names>Derya</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">New York University School of Medicine, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>tsuchiya@ttck.keio.ac.jp</email> (MT); <email>kumar@ttck.keio.ac.jp</email> (KS)</corresp><fn fn-type="con"><p>Conceived and designed the experiments: MH MT KS. Performed the experiments: MH MT KS. Analyzed the data: MH MT KS. Contributed reagents/materials/analysis tools: MT. Wrote the paper: MH JG JiI MT KS.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>2</day><month>3</month><year>2009</year></pub-date><volume>4</volume><issue>3</issue><elocation-id>e4661</elocation-id><history><date date-type="received"><day>11</day><month>12</month><year>2008</year></date><date date-type="accepted"><day>26</day><month>1</month><year>2009</year></date></history><copyright-statement>Helmy et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><p>The Toll-like receptor (TLR) 3 plays a critical role in mammalian innate immune response against viral attacks by recognizing double-stranded RNA (dsRNA) or its synthetic analog polyinosinic-polycytidylic acid (poly (I&#x02236;C)). This leads to the activation of MAP kinases and NF-&#x003ba;B which results in the induction of type I interferons and proinflammatory cytokines to combat the viral infection. To understand the complex interplay of the various intracellular signaling molecules in the regulation of NF-&#x003ba;B and MAP kinases, we developed a computational TLR3 model based upon perturbation-response approach. We curated literature and databases to determine the TLR3 signaling topology specifically for murine macrophages. For initial model creation, we used wildtype temporal activation profiles of MAP kinases and NF-&#x003ba;B and, for model testing, used TRAF6 KO and TRADD KO data. From dynamic simulations we predict i) the existence of missing intermediary steps between extracellular poly (I&#x02236;C) stimulation and intracellular TLR3 binding, and ii) the presence of a novel pathway which is essential for JNK and p38, but not NF-&#x003ba;B, activation. Our work shows activation dynamics of signaling molecules can be used in conjunction with perturbation-response models to decipher novel signaling features of complicated immune pathways.</p></abstract><counts><page-count count="10"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Toll-Like Receptors (TLRs) play a major role in innate immunity, the first line of mammalian defense against invading pathogens and crucial for antigen-specific acquired immunity development <xref ref-type="bibr" rid="pone.0004661-Takeda1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Akira1">&#x0005b;2&#x0005d;</xref>. Upon the recognition of pathogen-associated molecular patterns (PAMPs), such as bacterial lipopolysaccharide (LPS) and viral dsRNA, the 13 currently known TLRs trigger predominantly the activation of MAP kinases and several key transcription factors including nuclear factor-&#x003ba;B (NF-&#x003ba;B), activator protein (AP)-1 and interferon regulatory factor (IRF)- 3 and 7. This results in the induction of numerous proinflammatory cytokines and type I interferons <xref ref-type="bibr" rid="pone.0004661-Krishnan1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Lee1">&#x0005b;4&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Boehme1">&#x0005b;5&#x0005d;</xref>. The dysregulation of TLR signaling, therefore, has been attributed to the pathogenesis of major pro-inflammatory illnesses such as the autoimmune diseases <xref ref-type="bibr" rid="pone.0004661-Hulejova1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Bach1">&#x0005b;7&#x0005d;</xref>.</p><p>TLR3, one of the 4 known intracellular members of TLR family, recognizes dsRNA and poly (I&#x02236;C) <xref ref-type="bibr" rid="pone.0004661-Krishnan1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Boehme1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Matsumoto1">&#x0005b;8&#x0005d;</xref> triggers an innate response independent of the adaptor protein Myeloid Differentiation factor 88 (MyD88), which is required for all other TLRs <xref ref-type="bibr" rid="pone.0004661-Matsumoto1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Johnson1">&#x0005b;9&#x0005d;</xref>. The specificity of TLR3 response is possibly due to the occurrence of an alanine residue in a critical region of its cytoplasmic domain unlike the proline residue utilized by MyD88 found in other TLRs <xref ref-type="bibr" rid="pone.0004661-Boehme1">&#x0005b;5&#x0005d;</xref>. Thus, TLR3 initiates its response depending only on the adaptor protein TIR domain-containing adapter-including interferon-&#x003b2; (TRIF) <xref ref-type="bibr" rid="pone.0004661-Akira1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Matsumoto2">&#x0005b;10&#x0005d;</xref>. The recruitment of TRIF mediates the signaling process through the activation of key transcription factors NF-&#x003ba;B, AP-1, IRF-3 and 7 <xref ref-type="bibr" rid="pone.0004661-Krishnan1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Boehme1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Matsumoto1">&#x0005b;8&#x0005d;</xref>. Although the signaling molecules and their cascades have been broadly investigated, the dynamic outcome of signal transduction between wildtype and genetic mutations still remains poorly understood.</p><p>Here, we began the investigation of TLR3 pathway by literature/database curation of the signaling topology in murine macrophages. Next, we analyzed the temporal experimental data of wildtype, TNF Receptor Associated Factor (TRAF)-6 and NFRSF1A-associated via death domain (TRADD)-deficient murine macrophages with poly (I&#x02236;C) stimulation <xref ref-type="bibr" rid="pone.0004661-Gohda1">&#x0005b;11&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0004661-Pobezinskaya1">&#x0005b;12&#x0005d;</xref> by developing a computational TLR3 model based on perturbation-response approach. This approach does not require the detailed reaction kinetics of each reaction in the signaling topology (as in bottom-up approaches), but rather, considers the activation of signaling molecules as linear response events <xref ref-type="bibr" rid="pone.0004661-Selvarajoo1">&#x0005b;13&#x0005d;</xref>. Similar modeling approaches have been previously used to infer important biological network features; inferring feedback control of IKK activity in tumour-necrosis factor (TNF) stimulation <xref ref-type="bibr" rid="pone.0004661-Werner1">&#x0005b;14&#x0005d;</xref>, uncovering switching behaviour of MAPK signaling between epidermal growth factor (EGF) and neuronal growth factor (NGF) stimuli <xref ref-type="bibr" rid="pone.0004661-Santos1">&#x0005b;15&#x0005d;</xref>, detecting connectivities of reaction molecules <xref ref-type="bibr" rid="pone.0004661-Vance1">&#x0005b;16&#x0005d;</xref>, predicting missing molecules in TLR4 signaling <xref ref-type="bibr" rid="pone.0004661-Selvarajoo2">&#x0005b;17&#x0005d;</xref> and <italic>signaling flux redistribution</italic> (<italic>SFR</italic>) at pathway junctions <xref ref-type="bibr" rid="pone.0004661-Selvarajoo3">&#x0005b;18&#x0005d;</xref>.</p><p>Our TLR3 model simulations were compared with temporal experimental data of NF-&#x003ba;B, JNK and p38 in three experimental conditions; wildtype, TRAF6-deficient and TRADD-deficient macrophages. Collectively, the results suggest i) the existence of novel intermediary steps (e.g. missing cellular processes, proteins or phosphorylation states) between extracellular poly (I&#x02236;C) stimulation and intracellular TLR3 binding, and ii) the presence of a novel pathway which is essential for JNK and p38 activation.</p></sec><sec id="s2"><title>Results and Discussion</title><sec id="s2a"><title>Determination of the TLR3 signaling topology in macrophages</title><p>TLR3 is expressed in several cell types including macrophages, murine embryonic fibroblasts (MEFs) and dendritic cells (DCs), however, it was not found in B Cells, T Cells and NK cells <xref ref-type="bibr" rid="pone.0004661-Matsumoto1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Cario1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Muzio1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Visintin1">&#x0005b;21&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Matsumoto3">&#x0005b;22&#x0005d;</xref>. Moreover, the experimental observations of TLR3 signaling under various genetic knock-outs show controversial roles of certain molecules in different cell types. For instance, Gohda <italic>et al.</italic><xref ref-type="bibr" rid="pone.0004661-Gohda1">&#x0005b;11&#x0005d;</xref> showed that TRAF6 is dispensable for TLR3 induced NF-&#x003ba;B in poly (I&#x02236;C) stimulated macrophages, while Jiang <italic>et al.</italic><xref ref-type="bibr" rid="pone.0004661-Jiang1">&#x0005b;23&#x0005d;</xref> showed the requirement of TRAF6 to NF-&#x003ba;B activation in MEFs. Also, for NF-&#x003ba;B and MAP kinases activation, TRADD is not critical in macrophages, whereas, it is important for MEFs <xref ref-type="bibr" rid="pone.0004661-Pobezinskaya1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Ermolaeva1">&#x0005b;24&#x0005d;</xref>. These data indicate that there is no common topology for TLR3 signaling and, therefore, we cannot combine data obtained from different cell types to create unified TLR3 signaling topology. Instead, independent cell type analysis should be performed.</p><p>Here, we investigate the signaling topology for murine macrophages only. It is known that TRIF interacts with TLR3 at the TIR domain and TRAF6 binds to the N-terminal of TRIF <xref ref-type="bibr" rid="pone.0004661-Matsumoto1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Gohda1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Sato1">&#x0005b;25&#x0005d;</xref>. However, we found, in murine macrophages, the role of TRAF6 in TLR3 signaling is dispensable <xref ref-type="bibr" rid="pone.0004661-Gohda1">&#x0005b;11&#x0005d;</xref>; the temporal experimental profiles of MAP kinases (JNK and p38) and NF-&#x003ba;B activation to poly (I&#x02236;C) stimulation in TRAF6 KO were only slightly reduced compared with wildtype levels (<xref ref-type="fig" rid="pone-0004661-g001">Figure 1A&#x02013;C</xref> WT and TRAF6 KO).</p><fig id="pone-0004661-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004661.g001</object-id><label>Figure 1</label><caption><title>NF-&#x003ba;B and JNK experimental activation profiles.</title><p>A), B) and C) show experimental activation profiles of NF-&#x003ba;B, JNK and p38, respectively in (WT) (black), TRAF6 KO (green), TRADD KO (orange) obtained from <xref ref-type="bibr" rid="pone.0004661-Gohda1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Pobezinskaya1">&#x0005b;12&#x0005d;</xref>. The activation levels were quantified from the western blots using ImageJ &#x0005b;<ext-link ext-link-type="uri" xlink:href="http://rsbweb.nih.gov/ij/">http://rsbweb.nih.gov/ij/</ext-link>&#x0005d;. The <italic>x</italic>-axis represents the time in minutes and the <italic>y</italic>-axis represents the relative activation profile. Note: As TRADD KO data is unavailable at 10 min (earliest at 15 min), we could not observe delayed activation of as noted for WT and TRAF6 KO. Therefore, we used dotted line to connect 0 min and 15 min time points.</p></caption><graphic xlink:href="pone.0004661.g001"/></fig><p>Recently, TRADD has been shown to be involved in the TLR3 signaling <xref ref-type="bibr" rid="pone.0004661-Gohda1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Ermolaeva1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Chen1">&#x0005b;26&#x0005d;</xref>. TRADD-deficient macrophages showed downregulation of MAP Kinases and a slight upregulation of NF-&#x003ba;B activation (<xref ref-type="fig" rid="pone-0004661-g001">Figure 1A&#x02013;C</xref> TRADD KO) <xref ref-type="bibr" rid="pone.0004661-Gohda1">&#x0005b;11&#x0005d;</xref>. RIP1, which binds to TRIF at C-terminal (RHIM domain), interacted with TRADD through death domain (DD) suggesting TRADD's possible involvement in RIP1 ubiquitination <xref ref-type="bibr" rid="pone.0004661-Pobezinskaya1">&#x0005b;12&#x0005d;</xref>. Since RIP1 is required for TRIF-dependent signaling in response to poly (I&#x02236;C) stimulation <xref ref-type="bibr" rid="pone.0004661-CussonHermance1">&#x0005b;27&#x0005d;</xref>, TRADD is likely involved in NF-&#x003ba;B activation via RIP1. Putting together, we created a macrophage TLR3 signaling topology (<xref ref-type="fig" rid="pone-0004661-g002">Figure 2A</xref>).</p><fig id="pone-0004661-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004661.g002</object-id><label>Figure 2</label><caption><title>Analysis of TLR3 pathway in macrophages.</title><p>A) Schematic representation of the determined TLR3 pathway topology in macrophages. dsRNA or poly (I&#x02236;C) stimulated TLR3 triggers TRIF dependant response by the recruitment of TRIF to the cytoplasmic domain of the receptor which then allows RIP1, TRAF6, TBK1 and TRAF3 to bind with TRIF. This results in the activation of MAP kinases (MKK1/2, MKK3/6 and MKK4/7) and I&#x003ba;B kinase complex; MKK1/2, MKK3/6 and MKK4/7 activate ERK, JNK and p38, respectively and I&#x003ba;B&#x003b1; degradation releases NF-&#x003ba;B. TBK1 phosphorylates IRF-3 and 7. ERK, JNK and p38 translocate to the nucleus and activate the transcription factor AP-1, and NF-&#x003ba;B, IRF-3 and IRF-7 translocate to the nucleus. AP-1 and NF-&#x003ba;B bind to the promoter regions of cytokine genes such as <italic>Tnf</italic> and <italic>Il6</italic> while IRF-3, IRF-7 together with NF-&#x003ba;B bind to the promoter region of chemokine genes such as <italic>Cxcl10</italic> and <italic>Ccl5</italic> and induce their transcription. Protein-protein interactions between molecules at the two signaling branches analyzed are highlighted in brown and blue. The dotted lines indicate weak activation (see maintext). B), C) and D) show simulations of NF-&#x003ba;B, JNK and p38 activation, respectively, in wildtype (WT). The <italic>x</italic>-axis represents the time in minutes and the <italic>y</italic>-axis represents the relative activation profile.</p></caption><graphic xlink:href="pone.0004661.g002"/></fig></sec><sec id="s2b"><title>The prediction of missing intermediary cellular processes in poly (I&#x02236;C) stimulated macrophages</title><p>So far, we have built the signaling topology for TLR3 pathways in macrophages. Next, to understand the complex dynamic interplay of the various intracellular signaling molecules in the regulation of NF-&#x003ba;B, JNK and p38 in poly (I&#x02236;C) stimulation, we developed a computational model of the TLR3 signaling (see <xref ref-type="sec" rid="s3">Materials and Methods</xref>). Each signaling response (i.e., the rate of activation of each signaling molecule) in the model is represented by <inline-formula><inline-graphic xlink:href="pone.0004661.e001.jpg" mimetype="image"/></inline-formula>, where &#x003b4;<bold><italic>X</italic></bold> is relative activated concentration of signaling molecules and the parameters (elements of <bold><italic>J</italic></bold>) are chosen to fit the semi-quantitative experimental profiles (e.g, western blots, EMSA, etc.) of NF-&#x003ba;B, JNK and p38 of wildtype macrophages stimulated with poly (I&#x02236;C) (<xref ref-type="fig" rid="pone-0004661-g001">Figure 1A&#x02013;C</xref> WT). As mentioned earlier, TRAF6 KO does not noticeably affect NF-&#x003ba;B, JNK or p38 activation compared to wildtype (<xref ref-type="fig" rid="pone-0004661-g001">Figure 1A&#x02013;C</xref>). Hence, in the model, we used a low parameter value between TRIF and TRAF6 to limit the response flux propagation through TRAF6 such that the removal of TRAF6 in the model will only slightly affect its downstream reactions (see <xref ref-type="sec" rid="s3">Materials and Methods</xref> for details).</p><p>We, next, simulated activation of NF-&#x003ba;B, JNK and p38 in wildtype. Our results show the time to reach peak values were 15&#x02013;20 min earlier than in actual experiments (<xref ref-type="fig" rid="pone-0004661-g002">Figure 2B&#x02013;D</xref>). Clearly, this model could not explain the delayed experimental activation of NF-&#x003ba;B, JNK and p38. We can consider time delay processes of signaling events are due to missing molecules/complex formation or spatial movement of molecules <xref ref-type="bibr" rid="pone.0004661-Selvarajoo1">&#x0005b;13&#x0005d;</xref>. The deterministic kinetic evolution equation used in our model, non-linear <bold><italic>F</italic></bold> in general (Eq.1, <xref ref-type="sec" rid="s3">Materials and Methods</xref>), can include such information by setting total derivative of time to partial derivative in time and space. In other words, Jacobian matrix <bold><italic>J</italic></bold> can contain temporal and spatial information of the network process. Since we are not performing spatial simulation, time delay response can be lumped as missing molecules/processes in the network. For example, using a TLR4 model, we previously predicted the delayed activation of TRIF-dependent pathways by using a number of additional response reactions representing missing signaling features (molecules/processes, spatial movements or complex formation) in the original network <xref ref-type="bibr" rid="pone.0004661-Selvarajoo2">&#x0005b;17&#x0005d;</xref>. Our result was later substantiated by McGettick <italic>et al.</italic>, 2006 <xref ref-type="bibr" rid="pone.0004661-McGettrick1">&#x0005b;28&#x0005d;</xref> who demonstrated two novel signaling molecules (PKC&#x003b5; and TRAM) act upstream of TRIF and, recently, by Kagan <italic>et al.</italic>, 2008 <xref ref-type="bibr" rid="pone.0004661-Kagan1">&#x0005b;29&#x0005d;</xref> who discovered that the internalization of TLR4 into the endosome is required prior to TRIF-dependent pathway activation. Thus, the delayed activation of NF-&#x003ba;B and MAP Kinases in poly (I&#x02236;C) stimulation could also be due to missing molecules or cellular processes.</p><p>To investigate and locate the likely position of the necessary missing intermediary steps in the TLR3 pathway predicted by the model, we further surveyed the literature. TRIF directly bind to the TIR domain of TLR3 and does not require TRAM for its activation <xref ref-type="bibr" rid="pone.0004661-Yamamoto1">&#x0005b;30&#x0005d;</xref>. Thus, it is unlikely that missing intermediary steps exist between TLR3 and TRIF. Furthermore, TLR3 KO and TRIF KO both showed similar response; abolished activation of NF-&#x003ba;B and MAP Kinases <xref ref-type="bibr" rid="pone.0004661-Yamamoto1">&#x0005b;30&#x0005d;</xref>. These data led us to hypothesize the missing intermediary steps (e.g. signaling molecules or processes) are upstream of TLR3 and we updated our model to begin simulation not from TLR3, but rather from poly (I&#x02236;C) downwards (<xref ref-type="fig" rid="pone-0004661-g003">Figure 3A</xref>). We also represented each new uncharacterized molecule/process as a signaling intermediate in our model.</p><fig id="pone-0004661-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004661.g003</object-id><label>Figure 3</label><caption><title>Prediction of missing steps prior to poly (I&#x02236;C)/TLR3 binding.</title><p>A) Schematic representation of TLR3 model after adding three signaling intermediates upstream of TLR3 representing uncharacterized cellular processes (blue) and TLR3-ectodomain dimerization (red dotted) (see maintext). Note: from our model, it is not possible to equate the three intermediary steps to represent exactly three actual biological events, since spatial transport processes might be one of candidates for the time delay. B), C) and D) show simulations of NF-&#x003ba;B, JNK and p38 activation, respectively, in the wildtype (WT) (black), TRAF6 KO (green), TRADD KO (orange). The <italic>x</italic>-axis represents the time in minutes and the <italic>y</italic>-axis represents the relative activation profile.</p></caption><graphic xlink:href="pone.0004661.g003"/></fig><p>To obtain the delayed activation of NF-&#x003ba;B and MAP kinases in accordance with experimental data of wildtype, that is, null activation till 10 min, peak values around 30 min and reduced activation after 60 min for all molecules (<xref ref-type="fig" rid="pone-0004661-g001">Figure 1A&#x02013;C</xref>), we were required to add three intermediary steps (signaling intermediates) (<xref ref-type="fig" rid="pone-0004661-g003">Figure 3B&#x02013;D</xref> WT). Having less or more intermediary steps resulted in peak value reaching faster or slower than experimental peak, respectively (data not shown).</p><p>While preparing this manuscript, Liu <italic>et al.</italic> demonstrated that TLR3-ectodomains dimerizes before signal propagation <xref ref-type="bibr" rid="pone.0004661-Liu1">&#x0005b;31&#x0005d;</xref>. Our prediction of novel intermediary steps in upstream of TLR3 activation indicates that TLR3-ectodomains dimerization could be one of the missing intermediary steps. The other intermediary steps could indicate the endocytosis of poly (I&#x02236;C) and its subsequent transport mechanisms to be recognized by TLR3.</p></sec><sec id="s2c"><title>The existence of missing pathway for MAP Kinases activation in poly (I&#x02236;C) stimulation</title><p>To further test the predictive capability of our model, we simulated TRAF6 KO and TRADD KO (see <xref ref-type="sec" rid="s3">Materials and Methods</xref>). We wondered whether the same TLR3 model could successfully simulate the activation of NF-&#x003ba;B, JNK and p38 in all three conditions: wildtype, TRAF6 KO and TRADD KO. To create KO condition from wildtype model, we set the reactions of the KO molecule null, while all other model parameters retain their original wildtype values.</p><p>The TRAF6 KO simulations matched the experimental data, i.e., the removal of TRAF6 only slightly downregulated NF-&#x003ba;B, JNK and p38 activation (<xref ref-type="fig" rid="pone-0004661-g003">Figure 3B&#x02013;D</xref> TRAF6 KO). For TRADD KO, NF-&#x003ba;B activation was slightly increased in experiments (<xref ref-type="fig" rid="pone-0004661-g001">Figure 1A</xref>). This result was recapitulated by our model which suggests the enhancement of NF-&#x003ba;B activation in TRADD KO is due to <italic>signaling flux redistribution</italic><xref ref-type="bibr" rid="pone.0004661-Selvarajoo3">&#x0005b;18&#x0005d;</xref> (<xref ref-type="fig" rid="pone-0004661-g003">Figure 3B</xref> TRADD KO). However, in contrasts to experimental results, which showed only a small downregulation, simulations of JNK and p38 showed almost abolished activation (<xref ref-type="fig" rid="pone-0004661-g003">Figure 3C&#x02013;D</xref> TRADD KO). Thus, our simulation failure suggests, in actual cells, a novel pathway might exist that compensate the loss of MAP Kinases activation in TRADD KO.</p><p>Macrophages with TRIF mutation treated with poly (I&#x02236;C) showed abolishment of MAP kinase ERK activation <xref ref-type="bibr" rid="pone.0004661-Hoebe1">&#x0005b;32&#x0005d;</xref> and all MAP kinases showed similar kinetics in wildtype and TRAF6 KO <xref ref-type="bibr" rid="pone.0004661-Gohda1">&#x0005b;11&#x0005d;</xref>. Thus, we added a pathway from TRIF to MAP kinases into our model (<xref ref-type="fig" rid="pone-0004661-g004">Figure 4A</xref> and <xref ref-type="table" rid="pone-0004661-t001">Table 1</xref>) and adjusted the parameter values between TRIF to RIP1, TRADD and the novel pathway to fit wildtype NF-&#x003ba;B, JNK and p38 activation. We re-performed the simulations of TRAF6 KO and TRADD KO. The final model simulations matched experimental outcome for all three conditions (<xref ref-type="fig" rid="pone-0004661-g004">Figure 4B&#x02013;D</xref>).</p><fig id="pone-0004661-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004661.g004</object-id><label>Figure 4</label><caption><title>A novel pathway is crucial for MAP kinases activation in poly (I&#x02236;C) stimulated macrophages.</title><p>A) Schematic representation of the final TLR3 model after adding novel pathway (blue) from TRIF activates MAP kinases. B), C) and D) show simulations of NF-&#x003ba;B, JNK and p38 activation, respectively, of the final macrophages TLR3 model with novel pathway, in wildtype (WT) (black), TRAF6 KO (green) and TRADD KO (orange). The <italic>x</italic>-axis represents the time in minutes and the <italic>y</italic>-axis represents the relative activation profile.</p></caption><graphic xlink:href="pone.0004661.g004"/></fig><table-wrap id="pone-0004661-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004661.t001</object-id><label>Table 1</label><caption><title>The final <italic>in silico</italic> TLR3 model reactions and parameter values.</title></caption><graphic id="pone-0004661-t001-1" xlink:href="pone.0004661.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004661-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Reaction</td><td align="left" rowspan="1" colspan="1">Formula</td><td align="left" rowspan="1" colspan="1">Parameter value (1/s)</td><td align="left" rowspan="1" colspan="1">Remarks</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>1</bold></td><td align="left" rowspan="1" colspan="1">IM1&#x02192;IM2</td><td align="left" rowspan="1" colspan="1">k1&#x0002a;IM1</td><td align="left" rowspan="1" colspan="1">k1&#x0200a;&#x0003d;&#x0200a;0.002</td><td align="left" rowspan="1" colspan="1">Novel intermediates acting upstream of TLR3 representing uncharacterized cellular events.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>2</bold></td><td align="left" rowspan="1" colspan="1">IM2&#x02192;IM3</td><td align="left" rowspan="1" colspan="1">k2&#x0002a;IM2</td><td align="left" rowspan="1" colspan="1">k2&#x0200a;&#x0003d;&#x0200a;0.002</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>3</bold></td><td align="left" rowspan="1" colspan="1">IM3&#x02192;TLR3</td><td align="left" rowspan="1" colspan="1">k3&#x0002a;IM3</td><td align="left" rowspan="1" colspan="1">k3&#x0200a;&#x0003d;&#x0200a;0.002</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>4</bold></td><td align="left" rowspan="1" colspan="1">TLR3&#x02192;TRIF</td><td align="left" rowspan="1" colspan="1">k4&#x0002a;TLR3</td><td align="left" rowspan="1" colspan="1">k4&#x0200a;&#x0003d;&#x0200a;0.001</td><td align="left" rowspan="1" colspan="1">TLR3 recruits TRIF.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>5</bold></td><td align="left" rowspan="1" colspan="1">TRIF&#x02192;TRAF6</td><td align="left" rowspan="1" colspan="1">k5&#x0002a; TRIF</td><td align="left" rowspan="1" colspan="1">k5&#x0200a;&#x0003d;&#x0200a;0.002</td><td align="left" rowspan="1" colspan="1">TRAF6 binds to TRIF.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>6</bold></td><td align="left" rowspan="1" colspan="1">TRIF&#x02192;IM4</td><td align="left" rowspan="1" colspan="1">k6&#x0002a;TRIF</td><td align="left" rowspan="1" colspan="1">k6&#x0200a;&#x0003d;&#x0200a;0.004</td><td align="left" rowspan="1" colspan="1">TRIF activates JNK through Novel pathway</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>7</bold></td><td align="left" rowspan="1" colspan="1">TRIF&#x02192;RIP1</td><td align="left" rowspan="1" colspan="1">k7&#x0002a;TRIF</td><td align="left" rowspan="1" colspan="1">k7&#x0200a;&#x0003d;&#x0200a;0.007</td><td align="left" rowspan="1" colspan="1">RIP1 binds to TRIF.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>8</bold></td><td align="left" rowspan="1" colspan="1">TRIF&#x02192;TRADD</td><td align="left" rowspan="1" colspan="1">k8&#x0002a;TRIF</td><td align="left" rowspan="1" colspan="1">k8&#x0200a;&#x0003d;&#x0200a;0.002</td><td align="left" rowspan="1" colspan="1">TRADD binds to TRIF.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>9</bold></td><td align="left" rowspan="1" colspan="1">TRIF&#x02192;TRAF3</td><td align="left" rowspan="1" colspan="1">k9&#x0002a; TRIF</td><td align="left" rowspan="1" colspan="1">k9&#x0200a;&#x0003d;&#x0200a;0. 01</td><td align="left" rowspan="1" colspan="1">TRAF3 binds to TRIF.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>10</bold></td><td align="left" rowspan="1" colspan="1">TRAF6&#x02192;TAB/TAK</td><td align="left" rowspan="1" colspan="1">k10&#x0002a;TARF6</td><td align="left" rowspan="1" colspan="1">k10&#x0200a;&#x0003d;&#x0200a;0.04</td><td align="left" rowspan="1" colspan="1">TRAF6 binds to TAB/TAK complex.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>11</bold></td><td align="left" rowspan="1" colspan="1">RIP1&#x02192;IKK</td><td align="left" rowspan="1" colspan="1">k11&#x0002a;RIP1</td><td align="left" rowspan="1" colspan="1">k11&#x0200a;&#x0003d;&#x0200a;0.04</td><td align="left" rowspan="1" colspan="1">RIP1 activated IKK complex.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>12</bold></td><td align="left" rowspan="1" colspan="1">TRADD&#x02192;RIP1</td><td align="left" rowspan="1" colspan="1">k12&#x0002a;TRADD</td><td align="left" rowspan="1" colspan="1">k12&#x0200a;&#x0003d;&#x0200a;0.0001</td><td align="left" rowspan="1" colspan="1">RIP1 ubiquitination through TRADD.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>13</bold></td><td align="left" rowspan="1" colspan="1">TRADD&#x02192;MKKK</td><td align="left" rowspan="1" colspan="1">k13&#x0002a;TRADD</td><td align="left" rowspan="1" colspan="1">k13&#x0200a;&#x0003d;&#x0200a;0.04</td><td align="left" rowspan="1" colspan="1">TRADD activates JNK and p38 corresponding MKKK.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>14</bold></td><td align="left" rowspan="1" colspan="1">MKKK&#x02192;MKK3/6</td><td align="left" rowspan="1" colspan="1">k14&#x0002a;MKKK</td><td align="left" rowspan="1" colspan="1">k14&#x0200a;&#x0003d;&#x0200a;0.04</td><td align="left" rowspan="1" colspan="1">MKKK activates JNK through activation of MKK3/6.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>15</bold></td><td align="left" rowspan="1" colspan="1">MKKK&#x02192;MKK4/7</td><td align="left" rowspan="1" colspan="1">k15&#x0002a;MKKK</td><td align="left" rowspan="1" colspan="1">k15&#x0200a;&#x0003d;&#x0200a;0.04</td><td align="left" rowspan="1" colspan="1">MKKK activates p38 through activation of MKK4/7.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>16</bold></td><td align="left" rowspan="1" colspan="1">TAB/TAK&#x02192;MKK4/7</td><td align="left" rowspan="1" colspan="1">k16&#x0002a; TAB/TAK</td><td align="left" rowspan="1" colspan="1">k16&#x0200a;&#x0003d;&#x0200a;0.03</td><td align="left" rowspan="1" colspan="1">Activation of MAP kinases and IKK via TAB/TAK complex.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>17</bold></td><td align="left" rowspan="1" colspan="1">TAB/TAK&#x02192;MKK3/6</td><td align="left" rowspan="1" colspan="1">k17&#x0002a;TAB/TAK</td><td align="left" rowspan="1" colspan="1">k17&#x0200a;&#x0003d;&#x0200a;0.007</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>18</bold></td><td align="left" rowspan="1" colspan="1">TAB/TAK&#x02192;IKK</td><td align="left" rowspan="1" colspan="1">k18&#x0002a; TAB/TAK</td><td align="left" rowspan="1" colspan="1">k18&#x0200a;&#x0003d;&#x0200a;0.9</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>19</bold></td><td align="left" rowspan="1" colspan="1">IM4&#x02192;MKK3/6</td><td align="left" rowspan="1" colspan="1">k19&#x0002a; IM4</td><td align="left" rowspan="1" colspan="1">k19&#x0200a;&#x0003d;&#x0200a;0.04</td><td align="left" rowspan="1" colspan="1">The novel pathway activates JNK.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>20</bold></td><td align="left" rowspan="1" colspan="1">IM4&#x02192;MKK4/7</td><td align="left" rowspan="1" colspan="1">k20&#x0002a; IM4</td><td align="left" rowspan="1" colspan="1">k20&#x0200a;&#x0003d;&#x0200a;0.04</td><td align="left" rowspan="1" colspan="1">The novel pathway activates p38.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>21</bold></td><td align="left" rowspan="1" colspan="1">IKK&#x02192;NF-&#x003ba;B/I&#x003ba;B</td><td align="left" rowspan="1" colspan="1">k21&#x0002a;IKK</td><td align="left" rowspan="1" colspan="1">k21&#x0200a;&#x0003d;&#x0200a;0.00167</td><td align="left" rowspan="1" colspan="1">Phosphorylation of I&#x003ba;B&#x003b1;/NF-&#x003ba;B via IKK complex.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>22</bold></td><td align="left" rowspan="1" colspan="1">IKK&#x02192;p105/Tp12</td><td align="left" rowspan="1" colspan="1">k22&#x0002a;IKK</td><td align="left" rowspan="1" colspan="1">k22&#x0200a;&#x0003d;&#x0200a;0.0009</td><td align="left" rowspan="1" colspan="1">Activation of ERK via IKK.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>23</bold></td><td align="left" rowspan="1" colspan="1">p105/Tp12&#x02192;MKK1/2</td><td align="left" rowspan="1" colspan="1">k23&#x0002a; p105/Tp12</td><td align="left" rowspan="1" colspan="1">k23&#x0200a;&#x0003d;&#x0200a;0.003</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>24</bold></td><td align="left" rowspan="1" colspan="1">NF-&#x003ba;B/I&#x003ba;B&#x02192;NF-&#x003ba;Bc</td><td align="left" rowspan="1" colspan="1">k24&#x0002a; NF-&#x003ba;B/I&#x003ba;B</td><td align="left" rowspan="1" colspan="1">k24&#x0200a;&#x0003d;&#x0200a;0.0333</td><td align="left" rowspan="1" colspan="1">Release of NF-&#x003ba;B after I&#x003ba;B phosphorylation.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>25</bold></td><td align="left" rowspan="1" colspan="1">NF-&#x003ba;Bc&#x02192;NF-&#x003ba;Bn</td><td align="left" rowspan="1" colspan="1">k25&#x0002a; NF-&#x003ba;Bc</td><td align="left" rowspan="1" colspan="1">k25&#x0200a;&#x0003d;&#x0200a;1.0</td><td align="left" rowspan="1" colspan="1">NF-&#x003ba;B translocate to the nucleus.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>26</bold></td><td align="left" rowspan="1" colspan="1">NF-&#x003ba;Bn&#x02192;NF-&#x003ba;Bdeg</td><td align="left" rowspan="1" colspan="1">k26&#x0002a; NF-&#x003ba;Bn</td><td align="left" rowspan="1" colspan="1">k26&#x0200a;&#x0003d;&#x0200a;0.99</td><td align="left" rowspan="1" colspan="1">NF-&#x003ba;B degradation.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>27</bold></td><td align="left" rowspan="1" colspan="1">MKK1/2&#x02192;ERKc</td><td align="left" rowspan="1" colspan="1">k27&#x0002a;MKK1/2</td><td align="left" rowspan="1" colspan="1">k27&#x0200a;&#x0003d;&#x0200a;0.0167</td><td align="left" rowspan="1" colspan="1">Activation of ERK via MKK1/2.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>28</bold></td><td align="left" rowspan="1" colspan="1">ERKc&#x02192;ERKn</td><td align="left" rowspan="1" colspan="1">k28&#x0002a; ERKc</td><td align="left" rowspan="1" colspan="1">k28&#x0200a;&#x0003d;&#x0200a;0.99</td><td align="left" rowspan="1" colspan="1">ERK translocate to the nucleus.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>29</bold></td><td align="left" rowspan="1" colspan="1">ERKn&#x02192;AP-1</td><td align="left" rowspan="1" colspan="1">k29&#x0002a; ERKn</td><td align="left" rowspan="1" colspan="1">k29&#x0200a;&#x0003d;&#x0200a;0.99</td><td align="left" rowspan="1" colspan="1">ERK activates AP1.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>30</bold></td><td align="left" rowspan="1" colspan="1">MKK3/6&#x02192;JNKc</td><td align="left" rowspan="1" colspan="1">k30&#x0002a;MKK3/6</td><td align="left" rowspan="1" colspan="1">k30&#x0200a;&#x0003d;&#x0200a;0.4</td><td align="left" rowspan="1" colspan="1">Activation of JNK via MKK3/6.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>31</bold></td><td align="left" rowspan="1" colspan="1">JNKc&#x02192;JNKn</td><td align="left" rowspan="1" colspan="1">k31&#x0002a;JNKc</td><td align="left" rowspan="1" colspan="1">k31&#x0200a;&#x0003d;&#x0200a;1.0</td><td align="left" rowspan="1" colspan="1">JNK translocate to the nucleus.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>32</bold></td><td align="left" rowspan="1" colspan="1">JNKn&#x02192;AP-1</td><td align="left" rowspan="1" colspan="1">k32&#x0002a; JNKn</td><td align="left" rowspan="1" colspan="1">k32&#x0200a;&#x0003d;&#x0200a;0.99</td><td align="left" rowspan="1" colspan="1">JNK activates AP1.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>33</bold></td><td align="left" rowspan="1" colspan="1">MKK4/7&#x02194;p38c</td><td align="left" rowspan="1" colspan="1">k33&#x0002a;MKK4/7</td><td align="left" rowspan="1" colspan="1">k33&#x0200a;&#x0003d;&#x0200a;0.4</td><td align="left" rowspan="1" colspan="1">Activation of p38 via MKK4/7.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>34</bold></td><td align="left" rowspan="1" colspan="1">p38c&#x02192;p38n</td><td align="left" rowspan="1" colspan="1">k34&#x0002a; p38c</td><td align="left" rowspan="1" colspan="1">k34&#x0200a;&#x0003d;&#x0200a;1.0</td><td align="left" rowspan="1" colspan="1">p38 translocates to the nucleus.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>35</bold></td><td align="left" rowspan="1" colspan="1">p38n&#x02192;AP-1</td><td align="left" rowspan="1" colspan="1">k35&#x0002a; p38n</td><td align="left" rowspan="1" colspan="1">k35&#x0200a;&#x0003d;&#x0200a;0.99</td><td align="left" rowspan="1" colspan="1">p38 activates AP1.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>36</bold></td><td align="left" rowspan="1" colspan="1">AP1&#x02192;AP-1deg</td><td align="left" rowspan="1" colspan="1">k36&#x0002a; AP1</td><td align="left" rowspan="1" colspan="1">k36&#x0200a;&#x0003d;&#x0200a;0.085</td><td align="left" rowspan="1" colspan="1">AP1 degradation.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>37</bold></td><td align="left" rowspan="1" colspan="1">TRAF3&#x02192;TBK1</td><td align="left" rowspan="1" colspan="1">k37&#x0002a;TRAF3</td><td align="left" rowspan="1" colspan="1">k37&#x0200a;&#x0003d;&#x0200a;0.0001</td><td align="left" rowspan="1" colspan="1">TRAF3-TBK1 interaction.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>38</bold></td><td align="left" rowspan="1" colspan="1">TBK1&#x02192;IRF-3/7c</td><td align="left" rowspan="1" colspan="1">k38&#x0002a;TBK1</td><td align="left" rowspan="1" colspan="1">k38&#x0200a;&#x0003d;&#x0200a;0.333</td><td align="left" rowspan="1" colspan="1">IRF3/7 binds TBK1.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>39</bold></td><td align="left" rowspan="1" colspan="1">IRF-3/7c&#x02192;IRF-3/7n</td><td align="left" rowspan="1" colspan="1">k39&#x0002a;IRF-3/7c</td><td align="left" rowspan="1" colspan="1">k39&#x0200a;&#x0003d;&#x0200a;0.000167</td><td align="left" rowspan="1" colspan="1">IRF3/7 translocate to the nucleus.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>40</bold></td><td align="left" rowspan="1" colspan="1">IRF-3/7n&#x02192;IRF-3/7deg</td><td align="left" rowspan="1" colspan="1">k40&#x0002a;IRF-3/7n</td><td align="left" rowspan="1" colspan="1">k40&#x0200a;&#x0003d;&#x0200a;0.0001</td><td align="left" rowspan="1" colspan="1">IRF3/7 degradation.</td></tr></tbody></table></table-wrap><p>To investigate other possible pathways for JNK and p38 activation in poly (I&#x02236;C) stimulation, reports indicate two other receptors known to recognize dsRNA; the retinoic-acid-inducible protein (RIG)-I and melanoma-differentiation-associated gene (MDA) 5 and, therefore, might be potential candidates <xref ref-type="bibr" rid="pone.0004661-Pindado1">&#x0005b;33&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Kato1">&#x0005b;34&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Takeuchi1">&#x0005b;35&#x0005d;</xref>. However, firstly, RIG-I is unable to recognize poly (I&#x02236;C) <xref ref-type="bibr" rid="pone.0004661-Pindado1">&#x0005b;33&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Takeuchi1">&#x0005b;35&#x0005d;</xref> and secondly, MDA5 signaling pathway is unknown to trigger MAP kinases <xref ref-type="bibr" rid="pone.0004661-Takeuchi1">&#x0005b;35&#x0005d;</xref>. Furthermore, TRIF mutation showed abolishment of ERK activation <xref ref-type="bibr" rid="pone.0004661-Hoebe1">&#x0005b;32&#x0005d;</xref> and all MAP kinases seem to possess similar kinetics in poly (I&#x02236;C) stimulation <xref ref-type="bibr" rid="pone.0004661-Gohda1">&#x0005b;11&#x0005d;</xref>. Taken together, these data suggest the predicted pathway for JNK and p38 activation is through TRIF and not by RIG-1 or MDA5.</p><p>To find the possible candidates to be involved in the novel pathway, we again surveyed the literature. The TRAF family members, six to-date, are well-known to bind to the TIR domain of TRIF with their C-terminal <xref ref-type="bibr" rid="pone.0004661-Lamkanfi1">&#x0005b;36&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Oganesyan1">&#x0005b;37&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Su1">&#x0005b;38&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Miggin1">&#x0005b;39&#x0005d;</xref>, while two members of the RIP family, RIP1 and RIP3, are found to interact with TRIF through the RHIM domain found in RIP1, RIP3 and TRIF <xref ref-type="bibr" rid="pone.0004661-Meylan1">&#x0005b;40&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Meylan2">&#x0005b;41&#x0005d;</xref>. RIP1, TRAF6 and TRAF3 already exist in the current TLR3 signaling, while TRAF1 was recently found to inhibit the TRIF-mediated signaling <xref ref-type="bibr" rid="pone.0004661-Su1">&#x0005b;38&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Miggin1">&#x0005b;39&#x0005d;</xref>. Thus, we suggest that RIP3, TRAF2, TRAF4 or TRAF5 may be part of the novel pathway activating JNK and p38.</p><p>In summary, the analysis of the poly (I&#x02236;C) stimulation in macrophages reveals the involvement of uncharacterized missing intermediary steps prior to TLR3 activation and the existence of a key pathway from TRIF to JNK and p38, but not NF-&#x003ba;B activation. Although further experimental validation is required to identify the uncharacterized processes and molecules nevertheless, we show that the simple mass-action linear response can represent activation dynamics of the TLR3 signaling, and can be used to predict novel features of complicated immune pathways.</p></sec></sec><sec sec-type="materials|methods" id="s3"><title>Materials and Methods</title><sec id="s3a"><title>Development of <italic>in silico</italic> TLR3 model using perturbation-response approach</title><p>The basic principle behind our perturbation-response approach is to induce a controlled perturbation of a certain (input) reaction molecule of a system, which is kept at steady-state, and monitor the response of the concentration/activation levels of other molecules (output) of the system. By finding a relationship between the input perturbation (e.g. poly (I&#x02236;C) stimulation) and output response (e.g. JNK, NF-&#x003ba;B activation), the mechanistic properties of the system such as network topology can be uncovered (e.g. novel TRIF-MAP Kinases pathway) without knowing each individual's detailed kinetics.</p><p>To illustrate our approach, let us perturb a stable biological network consisting of <italic>n</italic> molecules from reference (stable) steady-state. The deterministic kinetic evolution equation is<disp-formula><graphic xlink:href="pone.0004661.e002.jpg" mimetype="image" position="float"/><label>(1)</label></disp-formula>where the corresponding vector form of Eq. 1 is <inline-formula><inline-graphic xlink:href="pone.0004661.e003.jpg" mimetype="image"/></inline-formula>. <bold><italic>F</italic></bold> is a vector of any non-linear function of the molecules vectors <bold><italic>X</italic></bold>&#x0200a;&#x0003d;&#x0200a;(<italic>X<sub>1</sub></italic>, <italic>X<sub>2</sub></italic>, &#x02025;, <italic>X<sub>n</sub></italic>), which represents activated concentration levels of signaling molecules (for example through phosphorylation, binding concentration of transcription factors to promoter regions etc.). The response to perturbation can be written by <bold><italic>X</italic></bold>&#x0200a;&#x0003d;&#x0200a;<bold><italic>X</italic></bold><sub>0</sub>&#x0002b;&#x003b4;<bold><italic>X</italic></bold>, where <bold><italic>X</italic></bold><sub>0</sub> is reference steady-state vector and &#x003b4;<bold><italic>X</italic></bold> is relative response from the steady-states (&#x003b4;<bold><italic>X</italic></bold><italic><sub>t</sub></italic><sub>&#x0200a;&#x0003d;&#x0200a;<italic>0</italic></sub>&#x0200a;&#x0003d;&#x0200a;<bold>0</bold>).</p><p>The use of small perturbation around steady-state leads to important simplification to the evolution equation, which can be highly non-linear (Eq. 1), resulting in the approximation of the first-order term. In vector form, <inline-formula><inline-graphic xlink:href="pone.0004661.e004.jpg" mimetype="image"/></inline-formula>, noting that zeroth order term <bold><italic>F</italic></bold>(<bold><italic>X</italic></bold><sub>0</sub>)&#x0200a;&#x0003d;&#x0200a;0 at the steady-state <bold><italic>X</italic></bold><sub>0</sub> and the <italic>Jacobian</italic> matrix or linear stability matrix, <inline-formula><inline-graphic xlink:href="pone.0004661.e005.jpg" mimetype="image"/></inline-formula>. The elements of <italic>J</italic> are chosen by fitting &#x003b4;<bold><italic>X</italic></bold> with corresponding experimental profiles and knowing the network topology (e.g., activation causality). Hence, the amount of response (flux propagated) along a signaling pathway can be determined using the law of mass flow conservation with <italic>first order mass-action kinetics</italic>, <inline-formula><inline-graphic xlink:href="pone.0004661.e006.jpg" mimetype="image"/></inline-formula> (<xref ref-type="table" rid="pone-0004661-t001">Table 1</xref>) <xref ref-type="bibr" rid="pone.0004661-Selvarajoo1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Selvarajoo3">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Selvarajoo4">&#x0005b;42&#x0005d;</xref>. We considered all signaling response to be linear and sequential up to 90 min after poly (I&#x02236;C) stimulation (equation &#x0005b;2&#x0005d;) as apparent from the formation-depletion activation profiles (see Experiments, and <xref ref-type="sec" rid="s2">Results and Discussion</xref>). Although there will not be any issue for parameter sensitivity in our system because of linear events, multiple solutions of parameter space, <bold><italic>J</italic></bold>s, can occur <xref ref-type="bibr" rid="pone.0004661-Selvarajoo1">&#x0005b;13&#x0005d;</xref>. To overcome this, we compare our (wildtype) model with two other (TRAF6 KO and TRADD KO) experimental conditions (see Verification of Model Parameters).</p></sec><sec id="s3b"><title>Modeling strategy</title><p>We first curated the murine macrophage TLR3 signaling topology from current literature/database sources and by checking with relevant experimental data (<xref ref-type="fig" rid="pone-0004661-g005">Figure 5</xref>, step 1 and see <xref ref-type="sec" rid="s2">Results and Discussion</xref>) <xref ref-type="bibr" rid="pone.0004661-Gohda1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Pobezinskaya1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Liu1">&#x0005b;31&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Ermolaeva1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Meylan1">&#x0005b;40&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Meylan2">&#x0005b;41&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Kanehisa1">&#x0005b;43&#x0005d;</xref>. Next, using the topology, we developed a dynamic model of TLR3 signaling on the E-Cell simulation platform <xref ref-type="bibr" rid="pone.0004661-Takahashi1">&#x0005b;44&#x0005d;</xref> to simulate the dynamics of NF-&#x003ba;B and JNK activation (<xref ref-type="fig" rid="pone-0004661-g005">Figure 5</xref>, step 2). The parameters of our model (elements of Jacobian matrix <bold><italic>J</italic></bold>) were estimated by fitting the simulation profiles of NF-&#x003ba;B, JNK and p38 with corresponding activation profiles semi-quantified from immunoblots, obtained from wildtype macrophages <xref ref-type="bibr" rid="pone.0004661-Gohda1">&#x0005b;11&#x0005d;</xref> (<xref ref-type="fig" rid="pone-0004661-g005">Figure 5</xref>, step 3) (Note that our model works quantitatively if appropriate data is available). If the model successfully fits the wildtype profile of NF-&#x003ba;B and JNK, we accept the model and call it the Reference Model (<xref ref-type="fig" rid="pone-0004661-g005">Figure 5</xref>, step 4). Otherwise, if the model fails, we adjust the parameters values or model topology until the model is able to simultaneously fit the experimental profiles of NF-&#x003ba;B, JNK and p38 reasonably (<xref ref-type="fig" rid="pone-0004661-g005">Figure 5</xref>, step 5).</p><fig id="pone-0004661-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004661.g005</object-id><label>Figure 5</label><caption><title>The modeling strategy.</title><p>See maintext for details.</p></caption><graphic xlink:href="pone.0004661.g005"/></fig><p>The model simulation results were deemed acceptable by comparing the simulation profile with the experimentally semi-quantitative profile based on three criteria; i) time of activation onset, ii) time to reach peak, and iii) decay profile (<xref ref-type="fig" rid="pone-0004661-g005">Figure 5</xref> insert). For example, JNK experimental profile shows null activation until 10 min, peak activation at 30 min and decaying trend until 90 min (<xref ref-type="fig" rid="pone-0004661-g001">Figure 1B</xref>, WT). In our first simulation of JNK (<xref ref-type="fig" rid="pone-0004661-g002">Figure 2C</xref>, WT), the time of activation onset was almost instantaneous, peak at around 10 min, and complete decay after 60 min. This simulation, therefore, is considered BAD based on the three criteria which poorly matched (<xref ref-type="fig" rid="pone-0004661-g005">Figure 5</xref> insert, upper panel). On the other hand, after modifying the signaling topology by adding novel intermediary steps, the simulation improved on all three criteria and considered GOOD (<xref ref-type="fig" rid="pone-0004661-g003">Figure 3C</xref>, WT, and <xref ref-type="fig" rid="pone-0004661-g005">Figure 5</xref> insert, lower panel).</p></sec><sec id="s3c"><title>Verification of Model Parameters</title><p>There can be several parameter spaces for Jacobian matrix, <bold><italic>J</italic></bold>s, which could fit wildtype semi-quantitative activation profiles of NF-&#x003ba;B, JNK and p38. To reduce the parameter spaces, we performed an iterative two-mode process of model &#x0201c;creation&#x0201d; and &#x0201c;testing&#x0201d;; &#x0201c;Creation&#x0201d; is to develop and fit our model with published available semi-quantitative profiles of NF-&#x003ba;B and MAP kinases activity in wildtype (step 4). &#x0201c;Testing&#x0201d; is to optimize reaction networks and parameter values, obtained from step 4, by simulating the knockout (KO) conditions (TRAF6 KO and TRADD KO) and comparing the results with their respective experimental profiles of NF-&#x003ba;B and MAP kinases activation <xref ref-type="bibr" rid="pone.0004661-Gohda1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Pobezinskaya1">&#x0005b;12&#x0005d;</xref>. Each KO model was generated from the wildtype model by setting the parameters involving the KO molecule null. If our KO simulation does not compare well with experiments, we re-tune the model parameters till the model simulations fit the activation profiles of both wildtype and TRAF6 KO (<xref ref-type="fig" rid="pone-0004661-g005">Figure 5</xref> step 6). If unsuccessful, we modify the topology so that a better fit can be obtained, for example, adding novel signaling intermediates to obtain the delayed activation <xref ref-type="bibr" rid="pone.0004661-Selvarajoo2">&#x0005b;17&#x0005d;</xref> or crosstalk mechanism to provide an alternative source of activation in the KO condition <xref ref-type="bibr" rid="pone.0004661-Selvarajoo4">&#x0005b;42&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Selvarajoo5">&#x0005b;45&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004661-Selvarajoo6">&#x0005b;46&#x0005d;</xref> (<xref ref-type="fig" rid="pone-0004661-g005">Figure 5</xref> step 4, see <xref ref-type="sec" rid="s2">Results and Discussion</xref>). To avoid false prediction, we further check comparing the model simulation against TRADD KO. When the model fails at these steps, it implies that either <bold><italic>J</italic></bold> (parameter space) is not correct or the represented topology is insufficient. We repeat the procedure of modifying parameter values and topology until we obtained reasonable predictions for all 3 conditions (wildtype, TRAF6 KO and TRADD KO) at 6 time points (0, 10, 20, 30, 60 and 90 min). At this point, we accepted the model and called it the Robust Model (<xref ref-type="fig" rid="pone-0004661-g005">Figure 5</xref> step 7). Therefore, using steps 1&#x02013;7, we were able to identify missing or incorrect feature(s) of the TLR3 pathways. The final (robust) TLR3 model's equations and parameter values can be found in <xref ref-type="table" rid="pone-0004661-t001">Table 1</xref>.</p></sec><sec id="s3d"><title>Final TLR3 Response Model</title><p>Our final model consists of 34 molecules with 40 reactions and parameters developed after comparing with dynamics of 3 molecules (NF-&#x003ba;B, JNK and p38) at 6 time points (0, 10, 20, 30, 60 and 90 min) for 3 conditions (wildtype, TRAF6 KO and TRADD KO) (<xref ref-type="table" rid="pone-0004661-t001">Table 1</xref>).</p></sec><sec id="s3e"><title>Experiments on macrophages</title><p>We utilized our published time-course experimental data of NF-&#x003ba;B, JNK and p38 of wildtype (model creation) and TRAF6-deficient (model testing) macrophages with 10 &#x000b5;g/ml poly (I&#x02236;C) stimulation <xref ref-type="bibr" rid="pone.0004661-Gohda1">&#x0005b;11&#x0005d;</xref>. For further model testing, we utilized published experimental profile of NF-&#x003ba;B, JNK and p38 of TRADD-deficient macrophages with similar poly (I&#x02236;C) stimulation <xref ref-type="bibr" rid="pone.0004661-Pobezinskaya1">&#x0005b;12&#x0005d;</xref>. The activation levels of NF-&#x003ba;B, JNK and p38 (<xref ref-type="fig" rid="pone-0004661-g001">Figure 1A&#x02013;B</xref>, Figure S1A) were quantified from the western blots using ImageJ (<ext-link ext-link-type="uri" xlink:href="http://rsbweb.nih.gov/ij/">http://rsbweb.nih.gov/ij/</ext-link>).</p></sec></sec></body><back><ack><p>We would like to thank members of Systems Immunology Group at IAB, Keio University.</p></ack><ref-list><title>References</title><ref id="pone.0004661-Takeda1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><year>2005</year><article-title>Toll-like receptors in innate immunity.</article-title><source>International immunology</source><volume>17</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">15585605</pub-id></citation></ref><ref id="pone.0004661-Akira1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name></person-group><year>2004</year><article-title>Toll-like receptor signaling.</article-title><source>Nature reviews</source><volume>4</volume><fpage>499</fpage><lpage>511</lpage></citation></ref><ref id="pone.0004661-Krishnan1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>J</given-names></name><name><surname>Selvarajoo</surname><given-names>K</given-names></name><name><surname>Tsuchiya</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name></person-group><year>2007</year><article-title>Toll-like receptor signal transduction.</article-title><source>Experimental &#x00026; molecular medicine</source><volume>39</volume><fpage>421</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">17934330</pub-id></citation></ref><ref id="pone.0004661-Lee1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name></person-group><year>2007</year><article-title>Signaling pathways downstream of pattern-recognition receptors and their cross talk.</article-title><source>Annual review of biochemistry</source><volume>76</volume><fpage>447</fpage><lpage>480</lpage></citation></ref><ref id="pone.0004661-Boehme1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boehme</surname><given-names>KW</given-names></name><name><surname>Compton</surname><given-names>T</given-names></name></person-group><year>2004</year><article-title>Innate sensing of viruses by toll-like receptors.</article-title><source>Journal of virology</source><volume>78</volume><fpage>7867</fpage><lpage>7873</lpage><pub-id pub-id-type="pmid">15254159</pub-id></citation></ref><ref id="pone.0004661-Hulejova1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hulejova</surname><given-names>H</given-names></name><name><surname>Baresova</surname><given-names>V</given-names></name><name><surname>Klezl</surname><given-names>Z</given-names></name><name><surname>Polanska</surname><given-names>M</given-names></name><name><surname>Adam</surname><given-names>M</given-names></name><etal/></person-group><year>2007</year><article-title>Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone.</article-title><source>Cytokine</source><volume>38</volume><fpage>151</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">17689092</pub-id></citation></ref><ref id="pone.0004661-Bach1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bach</surname><given-names>JF</given-names></name></person-group><year>2005</year><article-title>A Toll-like trigger for autoimmune disease.</article-title><source>Nature medicine</source><volume>11</volume><fpage>120</fpage><lpage>121</lpage></citation></ref><ref id="pone.0004661-Matsumoto1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Funami</surname><given-names>K</given-names></name><name><surname>Oshiumi</surname><given-names>H</given-names></name><name><surname>Seya</surname><given-names>T</given-names></name></person-group><year>2004</year><article-title>Toll-like receptor 3: a link between toll-like receptor, interferon and viruses.</article-title><source>Microbiology and immunology</source><volume>48</volume><fpage>147</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">15031527</pub-id></citation></ref><ref id="pone.0004661-Johnson1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>AC</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Pearlman</surname><given-names>E</given-names></name></person-group><year>2008</year><article-title>MyD88 functions as a negative regulator of TLR3/TRIF-induced corneal inflammation by inhibiting activation of c-Jun N-terminal kinase.</article-title><source>The Journal of biological chemistry</source><volume>283</volume><fpage>3988</fpage><lpage>3996</lpage><pub-id pub-id-type="pmid">18057004</pub-id></citation></ref><ref id="pone.0004661-Matsumoto2"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Funami</surname><given-names>K</given-names></name><name><surname>Tanabe</surname><given-names>M</given-names></name><name><surname>Oshiumi</surname><given-names>H</given-names></name><name><surname>Shingai</surname><given-names>M</given-names></name><etal/></person-group><year>2003</year><article-title>Subcellular localization of Toll-like receptor 3 in human dendritic cells.</article-title><source>Journal of immunology</source><volume>171</volume><fpage>3154</fpage><lpage>3162</lpage></citation></ref><ref id="pone.0004661-Gohda1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gohda</surname><given-names>J</given-names></name><name><surname>Matsumura</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>J</given-names></name></person-group><year>2004</year><article-title>Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing adaptor-inducing IFN-beta (TRIF)-dependent pathway in TLR signaling.</article-title><source>Journal of immunology</source><volume>173</volume><fpage>2913</fpage><lpage>2917</lpage></citation></ref><ref id="pone.0004661-Pobezinskaya1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pobezinskaya</surname><given-names>YL</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Choksi</surname><given-names>S</given-names></name><name><surname>Morgan</surname><given-names>MJ</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><etal/></person-group><year>2008</year><article-title>The function of TRADD in signaling through tumor necrosis factor receptor 1 and TRIF-dependent Toll-like receptors.</article-title><source>Nature immunology</source><volume>9</volume><fpage>1047</fpage><lpage>1054</lpage><pub-id pub-id-type="pmid">18641653</pub-id></citation></ref><ref id="pone.0004661-Selvarajoo1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Selvarajoo</surname><given-names>K</given-names></name><name><surname>Tomita</surname><given-names>M</given-names></name><name><surname>Tsuchiya</surname><given-names>M</given-names></name></person-group><year>2008</year><article-title>Can complex cellular processes be understood by simple rules?</article-title><source>Journal of bioinformatics and computational biology: in press</source></citation></ref><ref id="pone.0004661-Werner1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Werner</surname><given-names>SL</given-names></name><name><surname>Barken</surname><given-names>D</given-names></name><name><surname>Hoffmann</surname><given-names>A</given-names></name></person-group><year>2005</year><article-title>Stimulus specificity of gene expression programs determined by temporal control of IKK activity.</article-title><source>Science</source><volume>309</volume><fpage>1857</fpage><lpage>1861</lpage><pub-id pub-id-type="pmid">16166517</pub-id></citation></ref><ref id="pone.0004661-Santos1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>SD</given-names></name><name><surname>Verveer</surname><given-names>PJ</given-names></name><name><surname>Bastiaens</surname><given-names>PI</given-names></name></person-group><year>2007</year><article-title>Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate.</article-title><source>Nature cell biology</source><volume>9</volume><fpage>324</fpage><lpage>330</lpage></citation></ref><ref id="pone.0004661-Vance1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vance</surname><given-names>W</given-names></name><name><surname>Arkin</surname><given-names>A</given-names></name><name><surname>Ross</surname><given-names>J</given-names></name></person-group><year>2002</year><article-title>Determination of causal connectivities of species in reaction networks.</article-title><source>Proceedings of the national academy of sciences of the United States of America</source><volume>99</volume><fpage>5816</fpage><lpage>5821</lpage><pub-id pub-id-type="pmid">11983885</pub-id></citation></ref><ref id="pone.0004661-Selvarajoo2"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Selvarajoo</surname><given-names>K</given-names></name></person-group><year>2006</year><article-title>Discovering differential activation machinery of the Toll-like receptor 4 signaling pathways in MyD88 knockouts.</article-title><source>FEBS letters</source><volume>580</volume><fpage>1457</fpage><lpage>1464</lpage><pub-id pub-id-type="pmid">16458306</pub-id></citation></ref><ref id="pone.0004661-Selvarajoo3"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Selvarajoo</surname><given-names>K</given-names></name><name><surname>Takada</surname><given-names>Y</given-names></name><name><surname>Gohda</surname><given-names>J</given-names></name><name><surname>Helmy</surname><given-names>M</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><etal/></person-group><year>2008</year><article-title>Signaling flux redistribution at toll-like receptor pathway junctions.</article-title><source>PLoS ONE</source><volume>3</volume><fpage>e3430</fpage><pub-id pub-id-type="pmid">18927610</pub-id></citation></ref><ref id="pone.0004661-Cario1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cario</surname><given-names>E</given-names></name><name><surname>Podolsky</surname><given-names>DK</given-names></name></person-group><year>2000</year><article-title>Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease.</article-title><source>Infection and immunity</source><volume>68</volume><fpage>7010</fpage><lpage>7017</lpage><pub-id pub-id-type="pmid">11083826</pub-id></citation></ref><ref id="pone.0004661-Muzio1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muzio</surname><given-names>M</given-names></name><name><surname>Bosisio</surname><given-names>D</given-names></name><name><surname>Polentarutti</surname><given-names>N</given-names></name><name><surname>D'Amico</surname><given-names>G</given-names></name><name><surname>Stoppacciaro</surname><given-names>A</given-names></name><etal/></person-group><year>2000</year><article-title>Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells.</article-title><source>Journal of immunology</source><volume>164</volume><fpage>5998</fpage><lpage>6004</lpage></citation></ref><ref id="pone.0004661-Visintin1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Visintin</surname><given-names>A</given-names></name><name><surname>Mazzoni</surname><given-names>A</given-names></name><name><surname>Spitzer</surname><given-names>JH</given-names></name><name><surname>Wyllie</surname><given-names>DH</given-names></name><name><surname>Dower</surname><given-names>SK</given-names></name><etal/></person-group><year>2001</year><article-title>Regulation of Toll-like receptors in human monocytes and dendritic cells.</article-title><source>Journal of immunology</source><volume>166</volume><fpage>249</fpage><lpage>255</lpage></citation></ref><ref id="pone.0004661-Matsumoto3"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Funami</surname><given-names>K</given-names></name><name><surname>Tanabe</surname><given-names>M</given-names></name><name><surname>Oshiumi</surname><given-names>H</given-names></name><name><surname>Shingai</surname><given-names>M</given-names></name><etal/></person-group><year>2003</year><article-title>Subcellular localization of Toll-like receptor 3 in human dendritic cells.</article-title><source>Journal of immunology</source><volume>171</volume><fpage>3154</fpage><lpage>3162</lpage></citation></ref><ref id="pone.0004661-Jiang1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name><name><surname>Sen</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><year>2004</year><article-title>Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta.</article-title><source>Proceedings of the national academy of sciences of the United States of America</source><volume>101</volume><fpage>3533</fpage><lpage>3538</lpage><pub-id pub-id-type="pmid">14982987</pub-id></citation></ref><ref id="pone.0004661-Ermolaeva1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ermolaeva</surname><given-names>MA</given-names></name><name><surname>Michallet</surname><given-names>MC</given-names></name><name><surname>Papadopoulou</surname><given-names>N</given-names></name><name><surname>Utermohlen</surname><given-names>O</given-names></name><name><surname>Kranidioti</surname><given-names>K</given-names></name><etal/></person-group><year>2008</year><article-title>Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses.</article-title><source>Nature immunology</source><volume>9</volume><fpage>1037</fpage><lpage>1046</lpage><pub-id pub-id-type="pmid">18641654</pub-id></citation></ref><ref id="pone.0004661-Sato1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Sugiyama</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Kawai</surname><given-names>T</given-names></name><etal/></person-group><year>2003</year><article-title>Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling.</article-title><source>Journal of immunology</source><volume>171</volume><fpage>4304</fpage><lpage>4310</lpage></citation></ref><ref id="pone.0004661-Chen1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>NJ</given-names></name><name><surname>Chio</surname><given-names>II</given-names></name><name><surname>Lin</surname><given-names>WJ</given-names></name><name><surname>Duncan</surname><given-names>G</given-names></name><name><surname>Chau</surname><given-names>H</given-names></name><etal/></person-group><year>2008</year><article-title>Beyond tumor necrosis factor receptor: TRADD signaling in toll-like receptors.</article-title><source>Proceedings of the national academy of sciences of the United States of America</source><volume>105</volume><fpage>12429</fpage><lpage>12434</lpage><pub-id pub-id-type="pmid">18719121</pub-id></citation></ref><ref id="pone.0004661-CussonHermance1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cusson-Hermance</surname><given-names>N</given-names></name><name><surname>Khurana</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name><name><surname>Kelliher</surname><given-names>MA</given-names></name></person-group><year>2005</year><article-title>Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation.</article-title><source>Journal of The Journal of biological chemistry</source><volume>280</volume><fpage>36560</fpage><lpage>36566</lpage></citation></ref><ref id="pone.0004661-McGettrick1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McGettrick</surname><given-names>AF</given-names></name><name><surname>Brint</surname><given-names>EK</given-names></name><name><surname>Palsson-McDermott</surname><given-names>EM</given-names></name><name><surname>Rowe</surname><given-names>DC</given-names></name><name><surname>Golenbock</surname><given-names>DT</given-names></name><etal/></person-group><year>2006</year><article-title>Trif-related adapter molecule is phosphorylated by PKC{epsilon} during Toll-like receptor 4 signaling.</article-title><source>Proceedings of the national academy of sciences of the United States of America</source><volume>103</volume><fpage>9196</fpage><lpage>9201</lpage><pub-id pub-id-type="pmid">16757566</pub-id></citation></ref><ref id="pone.0004661-Kagan1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kagan</surname><given-names>JC</given-names></name><name><surname>Su</surname><given-names>T</given-names></name><name><surname>Horng</surname><given-names>T</given-names></name><name><surname>Chow</surname><given-names>A</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><etal/></person-group><year>2008</year><article-title>TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta.</article-title><source>Nature immunology</source><volume>9</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">18297073</pub-id></citation></ref><ref id="pone.0004661-Yamamoto1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Hemmi</surname><given-names>H</given-names></name><name><surname>Uematsu</surname><given-names>S</given-names></name><name><surname>Hoshino</surname><given-names>K</given-names></name><etal/></person-group><year>2003</year><article-title>TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway.</article-title><source>Nature immunology</source><volume>4</volume><fpage>1144</fpage><lpage>1150</lpage><pub-id pub-id-type="pmid">14556004</pub-id></citation></ref><ref id="pone.0004661-Liu1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Botos</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Leonard</surname><given-names>JN</given-names></name><name><surname>Shiloach</surname><given-names>J</given-names></name><etal/></person-group><year>2008</year><article-title>Structural basis of toll-like receptor 3 signaling with double-stranded RNA.</article-title><source>Science</source><volume>320</volume><fpage>379</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">18420935</pub-id></citation></ref><ref id="pone.0004661-Hoebe1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoebe</surname><given-names>K</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Georgel</surname><given-names>P</given-names></name><name><surname>Janssen</surname><given-names>E</given-names></name><name><surname>Tabeta</surname><given-names>K</given-names></name><etal/></person-group><year>2003</year><article-title>Identification of Lps2 as a key transducer of MyD88-independent TIR signalling.</article-title><source>Nature</source><volume>424</volume><fpage>743</fpage><lpage>748</lpage><pub-id pub-id-type="pmid">12872135</pub-id></citation></ref><ref id="pone.0004661-Pindado1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pindado</surname><given-names>J</given-names></name><name><surname>Balsinde</surname><given-names>J</given-names></name><name><surname>Balboa</surname><given-names>MA</given-names></name></person-group><year>2007</year><article-title>TLR3-dependent induction of nitric oxide synthase in RAW 264.7 macrophage-like cells via a cytosolic phospholipase A2/cyclooxygenase-2 pathway.</article-title><source>Journal of immunology</source><volume>179</volume><fpage>4821</fpage><lpage>4828</lpage></citation></ref><ref id="pone.0004661-Kato1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Takeuchi</surname><given-names>O</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Yoneyama</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><etal/></person-group><year>2006</year><article-title>Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses.</article-title><source>Nature</source><volume>441</volume><fpage>101</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">16625202</pub-id></citation></ref><ref id="pone.0004661-Takeuchi1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>O</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><year>2008</year><article-title>MDA5/RIG-I and virus recognition.</article-title><source>Current opinion in immunology</source><volume>20</volume><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">18272355</pub-id></citation></ref><ref id="pone.0004661-Lamkanfi1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lamkanfi</surname><given-names>M</given-names></name><name><surname>D'Hondt</surname><given-names>K</given-names></name><name><surname>Vande Walle</surname><given-names>L</given-names></name><name><surname>van Gurp</surname><given-names>M</given-names></name><name><surname>Denecker</surname><given-names>G</given-names></name><etal/></person-group><year>2005</year><article-title>A novel caspase-2 complex containing TRAF2 and RIP1.</article-title><source>The Journal of biological chemistry</source><volume>280</volume><fpage>6923</fpage><lpage>6932</lpage><pub-id pub-id-type="pmid">15590671</pub-id></citation></ref><ref id="pone.0004661-Oganesyan1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oganesyan</surname><given-names>G</given-names></name><name><surname>Saha</surname><given-names>SK</given-names></name><name><surname>Guo</surname><given-names>B</given-names></name><name><surname>He</surname><given-names>JQ</given-names></name><name><surname>Shahangian</surname><given-names>A</given-names></name><etal/></person-group><year>2006</year><article-title>Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response.</article-title><source>Nature</source><volume>439</volume><fpage>208</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">16306936</pub-id></citation></ref><ref id="pone.0004661-Su1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Meng</surname><given-names>M</given-names></name><name><surname>Qian</surname><given-names>W</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><etal/></person-group><year>2006</year><article-title>TNF receptor-associated factor-1 (TRAF1) negatively regulates Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF)-mediated signaling.</article-title><source>European journal of immunology</source><volume>36</volume><fpage>199</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">16323247</pub-id></citation></ref><ref id="pone.0004661-Miggin1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miggin</surname><given-names>SM</given-names></name><name><surname>O'Neill</surname><given-names>LA</given-names></name></person-group><year>2006</year><article-title>New insights into the regulation of TLR signaling.</article-title><source>Journal of leukocyte biology</source><volume>80</volume><fpage>220</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">16698941</pub-id></citation></ref><ref id="pone.0004661-Meylan1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meylan</surname><given-names>E</given-names></name><name><surname>Burns</surname><given-names>K</given-names></name><name><surname>Hofmann</surname><given-names>K</given-names></name><name><surname>Blancheteau</surname><given-names>V</given-names></name><name><surname>Martinon</surname><given-names>F</given-names></name><etal/></person-group><year>2004</year><article-title>RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation.</article-title><source>Nature immunology</source><volume>5</volume><fpage>503</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">15064760</pub-id></citation></ref><ref id="pone.0004661-Meylan2"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meylan</surname><given-names>E</given-names></name><name><surname>Tschopp</surname><given-names>J</given-names></name></person-group><year>2005</year><article-title>The RIP kinases: crucial integrators of cellular stress.</article-title><source>Trends in biochemical sciences</source><volume>30</volume><fpage>151</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">15752987</pub-id></citation></ref><ref id="pone.0004661-Selvarajoo4"><label>42</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Selvarajoo</surname><given-names>K</given-names></name><name><surname>Tsuchiya</surname><given-names>M</given-names></name></person-group><year>2007</year><article-title>Systematic Determination of Biological Network Topology: Nointegral Connectivity Method (NICM).</article-title><person-group person-group-type="editor"><name><surname>Choi</surname><given-names>S</given-names></name></person-group><source>Introduction to Systems Biology.</source><publisher-loc>New Jersey</publisher-loc><publisher-name>The Humana Press, Inc</publisher-name><fpage>449</fpage><lpage>471</lpage></citation></ref><ref id="pone.0004661-Kanehisa1"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name></person-group><year>2000</year><article-title>KEGG: Kyoto encyclopedia of genes and genomes.</article-title><source>Nucleic acids research</source><volume>28</volume><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">10592173</pub-id></citation></ref><ref id="pone.0004661-Takahashi1"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Ishikawa</surname><given-names>N</given-names></name><name><surname>Sadamoto</surname><given-names>Y</given-names></name><name><surname>Sasamoto</surname><given-names>H</given-names></name><name><surname>Ohta</surname><given-names>S</given-names></name><etal/></person-group><year>2003</year><article-title>E-Cell 2: multi-platform E-Cell simulation system.</article-title><source>Bioinformatics (Oxford, England)</source><volume>19</volume><fpage>1727</fpage><lpage>1729</lpage></citation></ref><ref id="pone.0004661-Selvarajoo5"><label>45</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Selvarajoo</surname><given-names>K</given-names></name><name><surname>Helmy</surname><given-names>M</given-names></name><name><surname>Tomita</surname><given-names>M</given-names></name><name><surname>Tsuchiya</surname><given-names>M</given-names></name></person-group><year>2008</year><article-title>Inferring the mechanistic basis for the dynamic response of the MyD88-dependent and &#x02013;independent pathways.</article-title><source>10th International conference on molecular systems biology (ICSMB 2008)</source><publisher-loc>Manila, Philippines</publisher-loc><fpage>110</fpage><lpage>113</lpage></citation></ref><ref id="pone.0004661-Selvarajoo6"><label>46</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Selvarajoo</surname><given-names>K</given-names></name></person-group><year>2006</year><article-title>Decoding the Signaling Mechanism of Toll-Like Receptor 4 Pathways in Wild Type and Knockouts.</article-title><person-group person-group-type="editor"><name><surname>Ghosh</surname><given-names>S guest ed</given-names></name><name><surname>Arjunan</surname><given-names>SNV</given-names></name><name><surname>Tomita</surname><given-names>M</given-names></name><name><surname>Dhar</surname><given-names>PK</given-names></name></person-group><source>E-Cell System: Basic Concepts and Applications</source><publisher-name>Kluwer Academic Publishers - Landes Bioscience</publisher-name></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This study is funded by JST CREST, from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), Egyptian bureau of culture, sciences and education in Japan (M. Helmy) and by the Tsuruoka City, Yamagata prefecture. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 